Last reviewed · How we verify
Triptorelin pamoate（15mg）
Triptorelin pamoate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.
Triptorelin pamoate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Advanced prostate cancer, Hormone-responsive breast cancer, Endometriosis.
At a glance
| Generic name | Triptorelin pamoate（15mg） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that binds to GnRH receptors in the pituitary gland. Initial stimulation of GnRH receptors is followed by desensitization and downregulation, resulting in sustained suppression of gonadotropin secretion and consequent reduction in testosterone (in males) or estrogen (in females). This hormonal suppression is used therapeutically in hormone-dependent conditions.
Approved indications
- Advanced prostate cancer
- Hormone-responsive breast cancer
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Injection site reactions
- Decreased libido
- Erectile dysfunction
- Headache
- Fatigue
- Gynecomastia
- Transient increase in testosterone (flare)
Key clinical trials
- Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. (PHASE3)
- Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP (PHASE4)
- Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer (PHASE2)
- Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: